BioSpace News Archive

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022, prior to the open of the market.

Melinta Therapeutics, LLC (“Melinta”) and Cidara Therapeutics (“Cidara”) today announced that they have entered into a License Agreement (the “Agreement”) to facilitate a strategic partnership to commercialize rezafungin, a novel, once-weekly echinocandin antifungal in the United States (U.S.).

MiNK Therapeutics , Inc. announced it will release its second quarter 2022 financial results before the market opens on Tuesday, August 9th , 2022.

Amedisys, Inc. reported its financial results for the three and six-month periods ended June 30, 2022.

Lexicon Pharmaceuticals, Inc. announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001.

Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a virtual fireside chat at the upcoming 13th Annual Wedbush PacGrow Healthcare Conference.

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2022 financial results after the market closes on Wednesday, August 3, 2022.

Hologic, Inc. announced the Company’s financial results for the fiscal third quarter ended June 25, 2022.

Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will present at the following investor conferences in August:

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced revenue of $295.0 million for the quarter ended June 30, 2022, an increase of 5.2% compared to the quarter ended June 30, 2021.